Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats

Metabolism: Clinical and Experimental

Volumn 48, Issue 9, 1999, Pages 1141-1145

  Ihm, Sung Hee ^a   Yoo, Hyung Joon ^b   Park, Sung Woo ^b   Ihm, Jahei ^b  

^a Hankang Sacred Heart Hospital   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMINOGUANIDINE; CHOLESTEROL; GLUCOSE; LIPID HYDROPEROXIDE; MALONALDEHYDE; STREPTOZOCIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ERYTHROCYTE MEMBRANE; GLUCOSE BLOOD LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; LIPID PEROXIDATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 13044292629     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90128-2     Document Type: Article

References (31)

1. Sato Y, Hotta N, Sakamoto N, et al: Lipid peroxide level in plasma of diabetic patients. Biochem Med 21:104-107, 1979
2. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care 19:257-267, 1996
3. Semenkovich CF, Heinecke JW: The mystery of diabetes and atherosclerosis. Time for a new plot. Diabetes 46:327-334, 1997
4. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412, 1991
5. Kawamura M, Heinecke JW, Chait A: Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 94:771-778, 1994
6. Wolff SP, Dean RT: Glucose autoxidation and protein modification: The potential role of autoxidative glycosylation in diabetes. Biochem J 245:243-250, 1987
7. Hunt JV, Dean RT, Wolff SP: Hydroxyl radical production and autoxidative glycosylation: Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus. Biochem J 256:205-212, 1988
8. Brownlee M, Cerami A, Vlassara H: Advanced-glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
9. Bucala R, Makita Z, Koschinsky T, et al: Lipid advanced glycosylation: Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 90:434-438, 1993
10. Mullarke C, Edelstein D, Brownlee M: Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 13:932-939, 1990
11. Yan SD, Schmidt AM, Anderson GM, et al: Enhanced cellular oxidant stress by the interaction of advanced glycosylation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897, 1994
12. Brownlee M, Vlassara H, Kooney A, et al: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632, 1986
13. Ceriello A, Quatraro A, Giugliano D: New insight on non-enzymatic glycosylation may lead to therapeutic approaches for the prevention of diabetic complications. Diabet Med 9:297-299, 1992
14. Bucala R, Cerami A, Vlassara H: Advanced glycoslyation end products in diabetic complications. Diabetes Rev 3:258-268, 1995
15. Picard S, Parthasarathy S, Fruebis J, et al: Aminoguanidine inhibits the oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 89:6876-6880, 1992
16. Phihs-Tsimikas A, Parthasarathy S, Picard S, et al: Aminoguanidine has both pro-oxidant and antioxidant activity toward LDL. Arterioscler Thromb Vasc Biol 15:367-376, 1995
17. Odetti PR, Borgoglio A, Pascale A, et al: Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin. Diabetes 39:796-801, 1990
18. Kappus H, Diplock AT: Tolerance and safety of vitamin E: A toxicological position report. Free Radic Biol Med 13:55-74, 1992
19. Nourooz-Zadeh J, Tajaddini-Sarmadis J, McCarthy S, et al: Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 44:1054-1058, 1995
20. Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadis J, et al: Relationship between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia 40:647-653, 1997
21. Jain SK, McVie R, Duett J, et al: Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes. Diabetes 38:1539-1543, 1989
22. Mooradian AD, Dickerson F, Smith TL: Lipid order and composition of synaptic membranes in experimental diabetes mellitus. Neurochem Res 15:981-985, 1990
23. Gutteridge JMC, Halliwell B: The measurement and mechanism of lipid peroxidation in biological system. Trends Biochem Sci 15:129-135, 1990
24. Giardino I, Fard AK, Hatchell DL. et al: Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 47:1114-1120, 1998
25. Edelstein D, Brownlee M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41;26-29, 1992
26. Brownlee M: Glycation and diabetic complications. Diabetes 43:836-841, 1994
27. Berliner JA, Heinecke JW: The role of oxidized lipoproteins in atherogenesis. Free Radie Biol Med 20:707-727, 1996
28. Traub O, Van Bibber R: Role of nitric oxide in insulin-dependent diabetes mellitus-related vascular complications. West J Med 162:439-445, 1995
29. Reaven PD, Herold DA, Barnett T, et al: Effect of vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM. Diabetes Care 18:807-816, 1995
30. 2 and lipid peroxide levels in type 1 diabetic patients. Diabetes Care 21:1511-1516, 1998
31. Jain SK, McVie R, Jaramillo JJ, et al: Effect of modest vitamin E supplementation on blood glycated hemoglobin and triglyceride levels and red cells indices in type I diabetic patients. J Am Coll Nutr 15:458-461, 1996